Munich (ots/PRNewswire) - - Atrial fibrillation (AF) increases the risk of a severe stroke,[1] however almost half of patients are unaware of the risk[2] - The AFfect survey revealed that one in two patients had not heard of the condition at time of diagnosis[2] - World Stroke Day is on Saturday 29th October, find ...
Munich (ots/PRNewswire) - - Atrial fibrillation (AF) increases the risk of a severe stroke,[1] however almost half of patients are unaware of the risk[2] - The AFfect survey revealed that one in two patients had not heard of the condition at time of diagnosis[2] - World Stroke Day is on Saturday 29th October, find ...
Munich (ots/PRNewswire) - - Three abstracts highlight the economic burden of Venous Thromboembolism (VTE) in Europe and provide new insights into VTE treatment with LIXIANA®(edoxaban) - Daiichi Sankyo is committed to enhancing the understanding, prevention and treatment of VTE, and is partnering with the ...
Munich (ots/PRNewswire) - Results highlight the benefits of reduced dose edoxaban compared to warfarin in a potentially higher risk venous thromboembolism (VTE) patient population[1] Daiichi Sankyo Europe GmbH (hereafter Daiichi Sankyo) today announced data from a new analysis of the phase 3 Hokusai-VTE study, which ...
Munich (ots/PRNewswire) - This material is intended for global medical media only. For journalistic assessment and preparation before publication. Novo Nordisk today announced that semaglutide, an investigational glucagon-like peptide-1 (GLP-1) analogue administered once-weekly, significantly reduced the risk of the ...
Munich (ots/PRNewswire) - This material is intended for global medical media only. For journalistic assessment and preparation before publication. Novo Nordisk today announced that the progression of kidney damage was significantly lower with Victoza® treatment vs placebo, as measured by urinary albumin creatinine ratio, both added to standard of care in 9,340 adults ...
Munich (ots/PRNewswire) - This material is intended for global medical media only. For journalistic assessment and preparation before publication. Results from a post hoc analysis of the three-year part of the phase 3a SCALE (Satiety and Clinical Adiposity - Liraglutide Evidence) Obesity and Prediabetes trial show ...
Munich, Germany (ots/PRNewswire) - This material is intended for global medical media only. For journalistic assessment and preparation before publication. Novo Nordisk today presented data showing the odds of reaching fasting plasma glucose (FPG) targets without hypoglycaemia and weight gain were significantly ...
Munich (ots/PRNewswire) - This material is intended for global medical media only. For journalistic assessment and preparation before publication. Novo Nordisk today announced that semaglutide, an investigational glucagon-like peptide-1 (GLP-1) analogue administered once-weekly, significantly improved glycaemic ...
Munich (ots/PRNewswire) - Not for US or UK media - ENSURE-AF is the largest clinical trial of a non-vitamin K antagonist oral anticoagulant in patients with non-valvular atrial fibrillation - who undergo electrical cardioversion - ENSURE-AF is a Prospective, Randomized, Open-Label, Blinded E ndpoint evaluation ...
Munich (ots/PRNewswire) - Sub-analysis data from atrial fibrillation patient registry sponsored by Daiichi Sankyo reveals at-risk patient groups and recent trends in disease management[1],[2] Not for US media Daiichi Sankyo Europe GmbH (hereafter, Daiichi Sankyo) today announced data from new sub-analyses of the ...
Munich (ots/PRNewswire) - - ENSURE-AF results to be featured during a late-breaking clinical trial session - Five abstracts highlighting analyses from the global phase 3 ENGAGE AF-TIMI 48 study to be presented - Seven abstracts to reveal new findings from the PREFER in AF and VTE European patient registries Daiichi ...
Munich (ots/PRNewswire) - - Four abstracts highlight new subgroup analyses from the global phase 3 ENGAGE AF-TIMI 48 and Hokusai-VTE studies to be presented in oral and poster sessions Daiichi Sankyo Europe GmbH Group (hereafter, Daiichi Sankyo) today announced that data from three new subgroup analyses from the ...
Munich (ots/PRNewswire) - Daiichi Sankyo Europe GmbH (hereafter, Daiichi Sankyo) today announced that the German public health agency, The Federal Joint Committee (Gemeinsamer Bundesausschuss - G-BA), has granted an indication of a minor additional benefit for LIXIANA® (edoxaban), an oral, once-daily selective ...
Munich (ots/PRNewswire) - - On World Stroke Day (29 October) a campaign by Daiichi Sankyo highlights stroke risks associated with cardiovascular diseases - People with atrial fibrillation have a five times higher stroke risk compared to the general population.[1] In Europe less than 50% of patients with ...
Munich (ots/PRNewswire) - World Thrombosis Day Interactive Infographic [http://af-vte.thisinfographic.com/wtd ] Daiichi Sankyo is proud to partner with World Thrombosis Day [http://www.worldthrombosisday.org ] to promote vital global awareness of thrombosis, its causes, risk factors, and signs and symptoms. ...
Munich (ots/PRNewswire) - FOR EU MEDIA ONLY. NOT FOR UK MEDIA. - Daiichi Sankyo announces enrollment of first patient in ETNA-AF-Europe and the commencement of ETNA-VTE-Europe, two regional registries to collect robust information on how once-daily LIXIANA(R) is being used in real world settings - ETNA is a Daiichi Sankyo global initiative which will collect data ...
Munich (ots) - Introduction of new "Elements" completes the portfolio of automated, indication-specific planning tools for radiosurgery/SBRT The "Elements" strategy-indication-specific focused software applications aimed at enhancing the workflow for difficult to treat indications in the brain and spine introduced in 2013-comes full circle with the introduction of ...
Munich (ots/PRNewswire) - - Survey findings show that 97% of European cardiologists believe that non-valvular atrial fibrillation (NVAF) patients experience a delay in diagnosis,[1] which is associated with a higher risk of stroke[2] - European Cardiologists reveal the importance of reviewing patient ...
Montreal/Munich (ots) - Fund focuses on achieving human clinical proof-of-concept for early stage drug development projects, following a capital efficient investment approach in collaboration with Lilly TVM Capital Life Science, one of the leading life science venture capital firms in Canada, the United States and Europe, today announced the final closing of its latest ...
Munich (ots) - - Voluntary public tender offer expired - all offer conditions have been met - Circa 74.70 per cent of the outstanding preference shares of WMF have been tendered - Together with shares acquired outside the offer and in combination with shares held by FIBA, a shareholding quota of circa 90.30 per cent is reached - Squeeze-out of the remaining shareholders of WMF AG planned Finedining Capital GmbH ...
Medical Device UDIs & Traceability Forum
Munich (ots/PRNewswire) - **Ensure compliance with the new FDA and European Rules on Unique Device Identifiers** The FDA released the Final Rule on Unique Device Identifiers (UDIs) for all medical devices being sold or shipped into the US, and companion guidelines from the European Commission are due soon for Europe. In light of this, Healthcare IQ would like to stress ...
Munich, Germany (ots/PRNewswire) - For European Media Only, Not for UK Media Atrial fibrillation (AF) is the most common heart rhythm disorder[1] resulting in a five-fold increased risk of stroke compared with the general population[2] Daiichi Sankyo today announced its commitment to extend the PREvention oF ...
Munich (ots) - Kohlberg Kravis Roberts & Co. L.P. (together with its affiliates, "KKR") and funds advised by Permira ("Permira Funds") announce that Lavena Holding 1 GmbH ("LH1"), the holding company held jointly by KKR and the Permira Funds, is intending to sell in the market a total of 25 million shares of ProSiebenSat.1 Media AG ("ProSiebenSat.1"), by way of an accelerated book building to institutional investors. The ...
Munich, Germany (ots) - * Lack of patient adherence to hypertension treatment is one of the root causes of failure to reach blood pressure goals, contributing to increased risk of serious cardiovascular events * The Daiichi Sankyo myHypertensionCare patient support programme aims to improve patient engagement and ...
Munich (ots/PRNewswire) - The registry plans to gather data from more than 4,000 patients with VTE across seven European countries, providing insights into the clinical management of a disease that is a leading cause of morbidity and mortality[1] Daiichi Sankyo Europe GmbH announced the enrolment of the first ...
Munich And Calgary, Alberta (ots/PRNewswire) - -- Significant Increase in Functional HDL Persisted Throughout the 24-week Study Period -- -- Results from ASSURE Study Expected H1 2013, Using IVUS to Measure Regression of Atherosclerotic Plaque -- TSX Exchange Symbol: RVX Resverlogix Corp. today announced that the ...
Munich (ots/PRNewswire) - With the introduction of EchoNavigator and other new solutions, Philips paves the way for transformation in cardiovascular disease management Royal Philips Electronics will present a range of new and ground-breaking solutions, designed to demonstrate how innovation in patient-centered care ...
Munich (ots) - Jan Van Ruymbeke, 53, will become the new Chief Executive Officer of Daiichi Sankyo Europe this autumn. The native of Belgium will replace Reinhard Bauer, who is retiring after 10 years in this position. Van Ruymbeke will assume responsibility for the pharmaceutical company in October. Until the end ...
Munich (ots/PRNewswire) - **Not be used by UK media** To mark this year's World Hypertension Day, Daiichi Sankyo Europe has announced a website for patients offering more information about hypertension management and treatment. http://www.hypertensioncare.eu is now available to patients and physicians across Europe ...